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Abstract
Purpose: To describe a multimodal imaging diagnosis of retinopathy in dermatomyositis.
Case presentation: A 21-year-old white woman with a history of fatigue and a cutaneous rash complained of visual
impairment in her left eye. A funduscopic examination showed multiple confluent cotton-wool spots in both eyes.
Swept source-optical coherence tomography presented macular edema in both eyes; optical coherence tomography
angiography revealed superficial and deep capillary occlusion in all areas affected by cotton-wool spots; and fluorescein
angiography showed vascular walls enhancement, veins dilatation, and capillary leakage. After large doses of
intravenously administered glucocorticoid therapy, followed by a cyclophosphamide regimen, best corrected
visual acuity returned to 20/20 in both eyes.
Conclusions: This case report presents optical coherence tomography angiography clinical findings in a rare
case of dermatomyositis-associated retinopathy, remarking the importance of a multi-imaging approach for a
correct diagnosis and treatment of eye injuries, in order to avoid serious complications and permanent sequelae.
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Introduction
Retinopathy associated with dermatomyositis (DM) is
rare and was first described by Bruce in 1938 [1],
who presented two patients with ill-defined areas of
grayish-yellow exudate, roughly circular in shape and
varying in size, distended veins, and occasional deep
or superficial hemorrhage.
Since then, a few case reports have reported it in adults
and children with the same fundus appearance [2–7].
Further studies classified this clinical appearance
under the name of Purtscher-like retinopathy associated
with DM [8].
Purtscher retinopathy refers to a chorioretinopathy
associated with indirect trauma characterized by
funduscopic appearance with cotton-wool spots (CWS),
retinal hemorrhages, optic disc edema, and Purtscher
flecken (areas of inner retinal whitening), associated with
reduced visual acuity.
When typical retinal findings occur in the complete
absence of trauma, the term Purtscher-like retinopathy
is used. Purtscher-like retinopathy has been associated
with multiple clinical entities, including acute pan-
creatitis, pancreatic adenocarcinoma, renal failure, pre-
eclampsia and childbirth, connective tissue disorders,
crush injury, fat embolism syndrome, long bone fracture,
orthopedic surgery, Valsalva maneuver and weight-lifting,
lymphoproliferative disorders and bone marrow trans-
plantation, barotrauma, steroid injections in and around
the orbit and nasal passages, retrobulbar anesthesia,
hemolytic uremic syndrome, cryoglobulinemia, shaken
baby syndrome, and DM [9].
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DM has also been associated with other retinal path-
ology, such as central retinal artery occlusion [10], cen-
tral retinal vein occlusion [11], and optic neuropathy
[12]. In one report of 43 patients with polymyositis and
DM, only six (14%) had retinopathy [13]. However, when
the retina is affected visual prognosis is often poor with
an irreversible visual loss [14]. The presence of retino-
pathy with CWS has also been suggested as a sign of an
aggressive subtype of DM [6].
In this case report we describe a case of a 21-year-old
woman affected by acute DM associated with retinopathy.
A multimodal examination was carried out, which in-
cluded complete ophthalmoscopic fundus examination,
swept source-optical coherence tomography (SS-OCT),
fluorescein angiography (FA), and optical coherence
tomography angiography (OCTA), allowing us to better
understand the etiology and long-term sequelae.
SS-OCT is the latest milestone in retinal and choroidal
imaging. With its wavelength of 1050 nm, longer than
other spectral domain-optical coherence tomography
(SD-OCT 840 nm), it can overcome ocular opacities,
such as cataract or vitritis, thus allowing visualization of
the retina and choroid in eyes with disabled fundus view
[15]. Moreover, SS-OCT offers good visualization of the
retina and choroid with a single image acquisition with-
out the use of enhanced depth imaging (EDI) function.
FA gives information about the retinal vasculature,
analyzing their permeability to the injected dye.
OCTA is a non-invasive imaging technique that
employs motion contrast imaging to high-resolution volu-
metric blood flow information generating angiographic
images. Optical coherence tomography (OCT) angiograms
are en face images that can be scrolled outward from the
internal limiting membrane to the choroid to visualize the
individual vascular plexus and segment the inner retina,
outer retina, choriocapillaris, or other area of interest [16].
Case presentation
A 21-year-old white woman presented to our emergency
room with a 1-month history of fatigue, muscle aches,
nausea, cutaneous rash, and 5 days of blurred vision in
her left eye (OS).
She denied any double vision, pain with eye movements,
flashing lights, floaters, or changes in color vision. She had
no recent sick contacts or travel. She had no past ocular
or medical history. Her family history for ocular or
autoimmune disease was unremarkable. She used non-
steroidal anti-inflammatory drugs as needed for her
recent myalgia.
She presented with a malar rash and some violet raised
papules erupting on her elbows and knees that were
made worse by exposure to sunlight. Her arterial pres-
sure was 115/70 mmHg. Best corrected visual acuity was
20/20 in her right eye (OD) and 20/100 in her OS.
Intraocular pressure (IOP) was normal in both eyes
(OU). Extraocular movements were conjugate and full
and she had no subjective red desaturation. Conjunctiva
was white without dilated conjunctival vessels, cornea
was clear, and anterior chamber showed no evidence of
cell or flare, bilaterally.
On dilated examination she had bilateral retinal
vascular engorgement, scattered foci of inner retinal
whitening consistent with CWS, and some superficial
hemorrhages in OU.
These changes were primarily around the macula and
optic nerve and spared the peripheral retina (Fig. 1a).
Optic disks were pink with sharp margins and a cup-
to-disc ratio of approximately 0.4.
Triton Plus® SS-OCT (Topcon Corporation, Tokyo,
Japan) (Fig. 1b) showed light central macular edema in her
OD and severe central macular edema in her OS with the
presence of serous subretinal fluid. SS-OCT sections were
obtained on the CWS highlighting the presence of hyper-
reflective material affecting the nerve fiber layer and
reaching even the inner nuclear layer in some sections.
This is considered a sign of ischemia-induced edema.
Consistent with this edema, inner nuclear and outer plexi-
form layers appeared wavy and were partially masked by
the overlying CWS.
FA (Spectralis HRA+OCT; Heidelberg engineering,
Heidelberg, Germany) (Fig. 1c) showed generalized vas-
cular walls enhancement, veins dilatation, and capillary
leakage whereas, consistent with CWS, vascular occlu-
sion was observed.
Triton Plus® SS-OCTA (Topcon Corporation, Tokyo,
Japan) (Fig. 1d) confirmed superficial and deep capillary
occlusion in all areas affected by CWS, but these areas
appeared more confluent than in FA. No alterations
were visible in outer retina and choriocapillaris OCTA
segmentations, but some shadowing effects due to the
overlying CWS were present.
At presentation our patient had symptoms that indi-
cated myositis including diffuse muscle pain, weakness,
malar rash, and raised papules on elbows and knees. Her
muscle enzymes were significantly elevated with a creat-
ine kinase (CK) of 17,030 U/l (normal range 22–198 U/l)
and an aldolase (ALDOA) of 106 (normal range 0.5–3
UI/l). Electromyography and nerve conduction study
results were suggestive of moderate myositis and a sub-
sequent right thigh muscle (vastus lateralis) biopsy was
consistent with an inflammatory myopathy, showing
vascular inflammation and a perifascicular atrophy. A
myositis antibody panel was positive for an anti-Jo1 anti-
body. Given the constellation of findings our patient was
finally diagnosed as having DM.
Despite the absence of a clear consensus over the most
indicated retinal therapy [9], in agreement with a
rheumatologist who was managing the systemic disease,
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treatment was started with 1 mg/kg per day of orally ad-
ministered prednisone, but she showed no improvement
over the course of a week. Therefore, therapy was modi-
fied with the administration of a high dose of intraven-
ously administered methylprednisolone (1000 mg daily),
showing a slow favorable change after 1 week with a
reduction in macular edema and subretinal fluid.
At this point, a decision was taken to start a steroid-
sparing immunosuppressive drug, so the corticosteroids
were progressively tapered and therapy with cyclophos-
phamide was started.
The protocol for cyclophosphamide that was used was
500 mg/m2 (maximum 500mg) administered intraven-
ously every 2 weeks for the first three doses and then
750 mg/m2 (maximum 1200 mg) every 4 weeks for a
total of six doses, with no further cyclophosphamide in-
fusions. Thus, a standardized non-continuous treatment
protocol was used, with the cyclophosphamide treatment
course completed within 4 months of initiation [17, 18].
After 3 months of therapy, best corrected visual acuity
was returned to 20/20 in OU with subjective temporal
pericentral scotoma in her OS.
A funduscopic examination (Fig. 2a) revealed a reduction
in number and dimension of the CWS and some new
hemorrhages in OU.
SS-OCT (Fig. 2b) showed a complete resolution of the
cystoid macula edema and subretinal fluid. The ganglion
cell layer and, to a small extent, even the inner nuclear
layer were thinned in the areas previously affected by
CWS, confirming the ischemic nature of the edema. The
wavy appearance of inner nuclear layer and outer
plexiform layer was unchanged at this stage.
FA (Fig. 2c) showed normal diameters of arteries
and veins without wall enhancement. Consistent with
ischemic areas previously affected by CWS, capillary
and venule angioectasias were noticeable. However,
no retinal neovascularization was visible in OU.
OCTA (Fig. 2d) confirmed the same capillary occlu-
sions visible in FA and it detected venule angioectasias
as well.
After 6 months of therapy, CWS were almost com-
pletely resolved and no new hemorrhages were seen
(Fig. 3a,b). Best corrected visual acuity remained stable
at 20/20 in OU. However, the visual field examination
Fig. 1 Composite at time of diagnosis in left eye. a Fundus color picture: multiple confluent cotton-wool spots around the optic nerve head and
the macula; some superficial hemorrhages and moderate diffuse venous dilatations are also visible. b Swept source-optical coherence
tomography 6 mm scan (arrowheads for directions): severe central macular edema with the presence of serous subretinal fluid is shown. Scans
passing through cotton-wool spots show homogeneous hyper-reflective fiber layer as result of ischemic edema of nervous layer (blue arrow). The
edema in a few parts also involves the inner nuclear layer (yellow arrows), giving a thickened and hyper-reflective or hypo-reflective appearance.
Ganglion cell layer appears hyper-reflective and thickened in a few parts (stars). In the retinal areas affected by cotton-wool spots, inner nuclear
and outer plexiform layers appeared wavy (arrowheads). c Fluorescein angiography: vascular walls enhancement, veins dilatation, and capillary
occlusion where cotton-wool spots are present. d Optical coherence tomography angiography: superficial (D1) and deep (D2) capillary occlusion in all
the areas affected by cotton-wool spots are shown (red arrows)
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performed after disease resolution confirmed the pre-
sence of multiple and confluent scotomas in OU, with
central involvement in OS (Fig. 3c,d).
Discussion
Multimodal diagnostic evaluation has been used to
study Purtscher-like retinopathy in this case of DM.
Retinopathy in DM is a rare but a potentially blinding
entity. Although macular edema is reversible, ischemic
macular involvement can lead to severe irreversible
visual impairment.
It is reported that the pathogenesis of Purtscher’s
retinopathy and Purtscher-like retinopathy is linked to
the formation of several kinds of emboli, such as air, fat,
leukocyte aggregates, fibrin, platelets, and complement
activation [19].
DM is characterized pathologically by varying degrees
of perifascicular atrophy, vasculopathy, and perivascular
inflammation [20]. It has been proposed that inflamma-
tion and leukocyte aggregates induced by complement
activation may occlude the precapillary arterioles in the
human retina [19]. This process might also be facilitated
by the vasculitis due to the capillary endothelial damage
by inflammatory factors [8].
In our patient, SS-OCT, FA, and OCTA scans showed
typical vascular inflammatory signs and retinal inflam-
matory signs at presentation. In particular, OCT scans
revealed cystoid macular edema, subretinal fluid, and
ischemic edema of the inner retina, FA showed vascular
walls enhancement, veins dilatation, and capillary occlu-
sions, whereas OCTA confirmed capillary occlusions
and helped define their exact locations.
We are unaware of any report in the literature des-
cribing OCTA findings in retinopathy associated with
DM. In acute phase, this examination showed both
superficial and deep retinal capillary occlusion in the
same areas of FA, with ischemic areas more confluent
than in FA. It also excluded choriocapillary occlusions.
After the resolution of the inflammatory phase, SS-OCT
scans showed inner retina thinning as a result of ischemia,
FA showed permanent capillary occlusion, and OCTA
confirmed both superficial and deep retinal capillary
occlusion. A visual field examination showed permanent
scotomas in areas that corresponded to areas that were
previously affected by CWS.
These findings help to clarify the potential irreversible
visual impairment that can occur even after successful
disease resolution, as described in other studies [14]. In
Fig. 2 Composite after 3 months of therapy in left eye. a Fundus color picture: cotton-wool spots reduced in number and dimensions. New
hemorrhages appeared at fundus examination. b Swept source-optical coherence tomography 6 mm scan: no edema or subretinal fluid was
visible. Ganglion cell layer thinning is shown in all the areas previously affected by cotton-wool spots (blue arrow). Inner nuclear and outer
plexiform layers conserved their wavy aspect (arrowheads). The inner nuclear layer thinned in a few parts (yellow arrow). c Fluorescein
angiography: normal diameters of arteries and veins without wall enhancement are shown. Capillary and venule angioectasias inside ischemic
areas previously affected by cotton-wool spots are visible (red stars). d Optical coherence tomography angiography: superficial and deep capillary
occlusions (red arrows) and capillary angioectasias (red stars) are shown
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fact, if the macula is affected by complete capillary
occlusion or by retinal thinning of the inner nuclear
layer, visual prognosis remains poor.
Therefore, our suggestion in cases of Purtscher-like
retinopathy associated with DM is to come to a correct
diagnosis as fast as possible, start a treatment with high
doses of intravenously administered glucocorticoids in
agreement with a rheumatologist, and consider when to
switch to a steroid-sparing regimen with immuno-
suppressive therapy based on the clinical evolution. The
goal is to avoid ischemic damage extension and prevent
macular involvement.
Conclusion
The case presented notes the importance of a complete
ophthalmic examination with multimodal imaging in
cases of Purtscher-like retinopathy associated with DM. It
is essential to come to a diagnosis as fast as possible in
order to prevent retinal ischemic extension and macular
involvement, which are irreversible complications.
OCTA plays an important role in defining the early
ischemic damage and helps to localize the level of the
vascular occlusion. This is the first time that OCTA
characteristics are described in a case of Purtscher-like
retinopathy associated with DM and we believe that
OCTA could potentially replace FA in the early assess-
ment and follow up of a Purtscher-like retinopathy.
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Fig. 3 a, b Color fundus (a right eye; b left eye) after 6 months of immunosuppressive therapy. Cotton-wool spots and hemorrhages almost
resolved. c, d Visual fields of both eyes (c right eye; d left eye) assessed at the same time as color fundus. Although cotton-wool spots resolved,
visual field defects persist (C1 and D1, 30 degrees; C2 and D2, 5 degrees)
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